Use of nonclinical toxicity studies to support biosimilar antibody development.
| Autor: | Mihalcik L; Amgen Inc., One Amgen Drive, Thousand Oaks, CA, USA., Chow V; Amgen Inc., One Amgen Drive, Thousand Oaks, CA, USA., Ramchandani M; Amgen Inc., One Amgen Drive, Thousand Oaks, CA, USA., Hinkle B; Amgen Inc., One Amgen Drive, Thousand Oaks, CA, USA., McBride HJ; Amgen Inc., One Amgen Drive, Thousand Oaks, CA, USA., Lebrec H; Amgen Inc., One Amgen Drive, Thousand Oaks, CA, USA. Electronic address: hlebrec@amgen.com. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Regulatory toxicology and pharmacology : RTP [Regul Toxicol Pharmacol] 2021 Jun; Vol. 122, pp. 104912. Date of Electronic Publication: 2021 Mar 01. |
| DOI: | 10.1016/j.yrtph.2021.104912 |
| Databáze: | MEDLINE |
| Externí odkaz: |
|
Full Text from ScienceDirect